One study reported that reciprocal regulation between ADAM17 and miR-145 results in aberrant activation of the EGFR signaling, suggesting that inhibition of ADAM17 might be an ideal therapeutic strategy for the treatment of GBM. This evidence concerns the gene ADAM17 and glioblastoma.